

# RECENT CHANGES TO THE DRUG FORMULARIES

New Generics Added to the Formulary				
Generic Name	Brand Name	Common Use(s)	Commercial/Medicaid Formularies GH = Good Health; MD = Medicaid	Effective Date
tadalafil	Adcirca	PAH	<ul style="list-style-type: none"> <li>• GH: Tier 4 (Preferred Specialty)</li> <li>• MD: Tier 1 (Generic)</li> </ul>	4/4/2019
abiraterone 250mg	Zytiga	Cancer	<ul style="list-style-type: none"> <li>• GH: Tier 1 (Generic)</li> <li>• MD: Tier 1 (Generic)</li> </ul>	4/9/2019
solifenacin	Vesicare	Incontinence	<ul style="list-style-type: none"> <li>• GH: Tier 1 (Generic)</li> <li>• MD: Tier 1 (Generic)</li> </ul>	4/22/2019
ambrisentan	Letairis	PAH	<ul style="list-style-type: none"> <li>• GH: Tier 4 (Preferred Specialty)</li> <li>• MD: Tier 1 (Generic)</li> </ul>	4/29/2019
mesalamine DR	Delzicol	Ulcerative colitis	<ul style="list-style-type: none"> <li>• GH: Tier 1 (Generic)</li> <li>• MD: Tier 1 (Generic)</li> </ul>	5/10/2019
bosentan	Tracleer	PAH	<ul style="list-style-type: none"> <li>• GH: Tier 4 (Preferred Specialty)</li> <li>• MD: Tier 1 (Generic)</li> </ul>	5/30/2019

# RECENT CHANGES TO THE DRUG FORMULARIES

## New Medications Added to the Formulary

DRUG	Common Use(s)	Average Wholesale Price/Month	Commercial/Medicaid Formularies GH = Good Health; MD = Medicaid	Effective Date
Alora (estradiol) patch	Symptoms of Menopause	\$116	<ul style="list-style-type: none"> <li>• GH: Tier 2 (Preferred Brand)</li> <li>• MD: Tier 2 (Brand)</li> </ul>	5/22/2019
Mavenclad (cladribine)	Multiple Sclerosis	\$9,917	<ul style="list-style-type: none"> <li>• GH: Tier 5 (Non-Preferred Specialty)</li> <li>• MD: Tier 2 (Brand-Specialty)</li> </ul>	6/14/2019
Mayzent (siponimod)	Multiple Sclerosis	\$8,700	<ul style="list-style-type: none"> <li>• GH: Tier 5 (Non-Preferred Specialty)</li> <li>• MD: Tier 2 (Brand-Specialty)</li> </ul>	6/14/2019
Spravato (esketamine)	Treatment resistant depression	\$8,496	<ul style="list-style-type: none"> <li>• GH: Tier 6 (Medical)</li> <li>• MD: Tier 3 (Medical)</li> </ul>	6/14/2019

# RECENT CHANGES TO THE DRUG FORMULARIES

<b>Other Formulary Changes</b>				
<b>Drug Name</b>	<b>PREVIOUS Coverage</b> GH = Good Health; MD = Medicaid	<b>NEW Coverage</b> GH = Good Health; MD = Medicaid	<b>Comments</b>	<b>Effective Date</b>
Xarelto (rivaroxaban) 10mg	<ul style="list-style-type: none"> <li>• GH: Tier 2 ( Preferred Brand) w/ QL</li> <li>• MD: Tier 2 (Brand) w/QL</li> </ul>	<ul style="list-style-type: none"> <li>• GH: Tier 2 ( Preferred Brand)</li> <li>• MD: Tier 2 (Brand)</li> </ul>	Removed Quantity Limit (QL)	6/1/2019
First Mouthwash	<ul style="list-style-type: none"> <li>• GH:Not Covered</li> <li>• MD: Tier 2 (Brand)</li> </ul>	<ul style="list-style-type: none"> <li>• GH: Not Covered</li> <li>• MD: Not Covered</li> </ul>	Changed MD coverage to Not Covered	6/1/2019
<b>Drug Recalls or Withdrawals</b>				
<b>Drug Name</b>	<b>Recall Type</b>	<b>Reason for Recall</b>	<b>Actions to Take</b>	<b>Effective Date</b>
Losartan+HCTZ	Voluntary	Potential cancer causing agents	Sent letters to Members and Providers affected	4/30/2019
fentanyl patch	Voluntary	Potential for wrong strength of patch in box	Sent letters to Members and Providers affected	5/3/2019
Losartan	Voluntary	Potential cancer causing agents	Sent letters to Members and Providers affected	5/7/2019